Icosagen Completes €45 Million Expansion to Integrate Biologics Discovery, Development, and GMP Manufacturing at Single Estonia Site

Icosagen, an Estonia-based biotechnology company specializing in protein-based biotherapeutics, announced the completion of a €45 million (US$51 million) strategic expansion integrating biologics discovery, development, and current good manufacturing practice (GMP) manufacturing capabilities at a single site in Tartu, Estonia. The investment is supported by an €18 million (US$21 million) loan from the European Investment Bank (EIB) under the InvestEU program combined with Icosagen's own funding. The funding will support a new state-of-the-art single-use GMP manufacturing facility operating under European GMP regulatory requirements.¹

"It strengthens our ability to connect early therapeutic protein development with CMC [chemistry, manufacturing, and controls] and GMP manufacturing in one integrated pathway, with fewer handovers and a deeper understanding of each molecule from the start," said Mart Ustav, PhD, founder and CEO of Icosagen, in a company press release.¹

What capabilities does the expanded Icosagen facility now offer biotechnology and biopharmaceutical clients?

The expansion consolidates antibody discovery, protein engineering, transient expression, developability assessment, stable Chinese hamster ovary cell line (IcoCell) development, upstream and downstream process development, analytical characterization, and GMP manufacturing within a single integrated organization and physical site. This structure is designed to support biotechnology and biopharmaceutical companies globally across discovery, developability assessment, CMC development, and phase 1/2 GMP manufacturing for clinical supply, according to the company.

Icosagen has operated for nearly 3 decades in therapeutic protein discovery, engineering, expression, purification, and analytical characterization. It employs more than 200 scientists with experience in technically demanding biologic modalities, including multispecific antibodies and antibody-derived formats, according to the release.

What is the rationale for integrating early developability assessment with downstream CMC and manufacturing functions?

Fragmented biologics development pathways, in which discovery, process development, and GMP manufacturing occur across separate organizations or sites, have been associated with technical risk accumulating late in development, when manufacturability or formulation issues identified during scale-up can require costly reformulation or process redesign.² Integrating developability and manufacturability assessment earlier in the discovery process is intended to identify technical risks before formal CMC development begins. This strategy is consistent with broader industry efforts to reduce attrition and timeline extensions associated with complex biologic modalities such as multispecific antibodies and other non-standard antibody formats that do not conform to conventional manufacturing platforms.³

"For complex candidates, the goal is not to force every molecule into a conventional template, but to build a development and manufacturing strategy that fits the biology," Dr Ustav said in the release.¹

How does this investment fit within the broader European biomanufacturing and biotech funding landscape?

The EIB's €18 million (US$21 million) loan was issued under the InvestEU program, which consolidates European Union financial instruments to support investment in strategic priorities, including technological innovation and the bioeconomy. The investment reflects a broader European policy emphasis on strengthening domestic biomanufacturing capacity and reducing dependence on external, often non-European, contract development and manufacturing organizations (CDMOs) for clinical-stage biologic production.⁴

"With this investment, the EIB is supporting a fully integrated model that connects discovery to clinical manufacturing in one place —helping European innovators bring complex biologics to patients faster, while reducing reliance on external manufacturing capacities," said EIB Vice-President Karl Nehammer in the release.¹

What limitations apply to the expansion announcement, and what would clarify its practical impact for biopharma sponsors?

No specific client programs, therapeutic modalities, or molecules manufactured at the expanded facility were disclosed. The announcement describes capacity and capability expansion rather than completed or in-progress GMP manufacturing campaigns, and no production volume, batch capacity, or regulatory inspection history for the new facility was provided. Icosagen is an independent , family-owned company that did not disclose detailed financial or operational metrics beyond those included in its announcement, limiting independent assessment of capacity utilization or competitive positioning relative to established CDMOs in the European biologics manufacturing market.

References

1. Icosagen. PRESS RELEASE: Icosagen completes €45 million expansion, bringing therapeutic protein discovery, development and GMP manufacturing together under one roof. Published June 30, 2026. Accessed June 30, 2026. https://www.icosagen.com/news/icosagen-completes-e45-million-expansion-bringing-therapeutic-protein-discovery-development-and-gmp-manufacturing-together-under-one-roof/?_gl=1*6k10yp*_up*MQ..*_ga*MTc0MjMwODQ1Mi4xNzgyODQwNTk1*_ga_0E2XPGB08H*czE3ODI4NDA1OTQkbzEkZzEkdDE3ODI4NDA2MDEkajUzJGwwJGgw
2. Walsh G, Walsh E. Biopharmaceutical benchmarks 2022. Nat Biotechnol. 2022;40(12):1722-1760. doi:10.1038/s41587-022-01582-x
3. Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20(7):838-847. doi:10.1016/j.drudis.2015.02.008
4. European Commission. Proposal for a Critical Medicines Act. March 11, 2025. Accessed June 30, 2026. https://health.ec.europa.eu/publications/proposal-critical-medicines-act_en